ReviewInternational journal of molecular sciences2026
Perspectives on Colistin-An Old Antibiotic with Renewed Relevance in Modern Medicine.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk factors associated with carbapenem-resistant Gram-negative bacterial infections in intensive care units in Jordan.BMC infectious diseases · 2026Article
- Synergistic strategies to rescue the last-resort antibiotic colistin.Archives of microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance among bacteria represents a major challenge in modern medicine. The absence of antibiotics effective against multidrug-resistant pathogens triggers interest in reviving older antibiotics. This review aims to provide a focused and updated perspective on the reintroduction of polymyxin antibiotics, with a particular emphasis on colistin, a cyclic oligopeptide initially used in the 1950s and 1960s. We analyze colistin from multiple perspectives, including (i) its historical and contemporary clinical applications, (ii) pharmacokinetic and pharmacodynamic properties, and (iii) use in veterinary medicine and animal husbandry. Key unresolved issues are highlighted, such as colistin toxicity, challenges in susceptibility testing, the emergence of resistance, including the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.